Travatan Z (Travoprost Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 4, 2019 Category: Drugs & Pharmacology Source Type: news
Glaukos ’ iStent Has Strong Showing in 5-Year Data
This study shows that not only are Glaukos’ iStents as effective as once-daily topical travoprost in controlling IOP, but they also succeed at maintaining IOP reductions over the long-term with fewer additional medications.â€
The San Clemente, CA-based company has been on full court press for a while now. Earlier this year, at the 37th annual J.P. Morgan Healthcare Conference, the company unveiled a series of products and initiatives that would see it transition into a hybrid surgical, pharmaceutical, and medical device company.
Â
 (Source: MDDI)
Source: MDDI - April 16, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
Glaukos touts 5-year study of glaucoma stents
This study shows that not only are Glaukos’ iStents as effective as once-daily topical travoprost in controlling IOP, but they also succeed at maintaining IOP reductions over the long-term with fewer additional medications.”
Three-year outcomes of this study were published in 2016 in Ophthalmology and Therapy. The most recent article detailing five-year outcomes may be accessed online here.
“This latest publication represents the first-ever five-year, protocol-driven, randomized evaluation of standalone iStent implantation in newly diagnosed glaucoma patients,” said Glaukos prez & CEO Thomas Burns. “Moreover,...
Source: Mass Device - April 15, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Clinical Trials Featured Implants News Well Optical/Ophthalmic Vision Glaukos Ivantis Source Type: news
Glaukos Keeps Its Eye on the Prize at J.P. Morgan
Glaukos is probably at the top of its game when it comes down to maintaining a presence in the micro-invasive glaucoma surgery (MIGS) market. The San Clemente, CA-based company reaffirmed its laser-like focus on the market during a presentation at the 37th annual J.P. Morgan Healthcare Conference earlier on Wednesday.
Glaukos’ CEO Thomas Burns began his presentation speaking on the strengths of the firm and its goals going forward.
“Our mission is aspirational,†Burns said. “As a company we are seeking to transform glaucoma therapy, and in doing so we ...
Source: MDDI - January 10, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
Glaukos touts IOP, medication use reductions in iStent trial
Glaukos (NYSE:GKOS) today released results from a study of its iStent trabecular micro-bypass stent exploring its use during cataract surgery in patients with severe open-angle glaucoma, touting significant reductions in intraocular pressure and medication use.
The San Clemente, Calif.-based company’s iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP.
Results were published in the January issue of the Journal of Glaucoma.
“Although the iStent is currently ...
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news
Glaukos touts Ph2 glaucoma trial for drug-eluting implant
Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients.
The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost within the eye and when it’s depleted, the iDose is removed and replaced.
Get the full story at our sister site, Drug Delivery Business News.
The post Glaukos touts Ph2 glaucoma trial for drug-eluting implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Glaukos Source Type: news
Glaukos wins FDA nod for IDE trial of iStent SA
Glaukos (NYSE:GKOS) said today it won FDA investigational device exemption to launch a pivotal study of its iStent SA trabecular micro-bypass system designed to treat glaucoma.
The San Clemente, Calif.-based company’s iStent SA is designed to reduce intraocular pressure in psuedophakic, mild-to-moderate open-angle, pigmentary or psuedoexfoliative glaucoma patients, the company said.
The system includes 2 micro-scale titanium stents in an auto-injection system which can be injected into trabecular meshwork locations through a single corneal entry point to restore physiological outflow of aqueous humor into the Sclemm...
Source: Mass Device - December 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Glaukos Source Type: news
Glaukos touts iStent study with topical travoprost
Glaukos (NYSE:GKOS) touted data today from a 53-patient glaucoma study showing that its iStent device combined with topical travoprost reduced mean intraocular pressure by 35% after 18 months of follow-up.
The company’s flagship device is designed to lessen IOP by restoring the natural outflow of aqueous humor through the conventional pathway in a patient’s eye.
Get the full story at our sister site, Drug Delivery Business News.
The post Glaukos touts iStent study with topical travoprost appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Stents Wall Street Beat Glaukos Source Type: news
Envisia reports positive interim results from Phase II trial of ENV515 in glaucoma
US-based clinical-stage biotechnology firm Envisia Therapeutics has reported positive interim results from the second cohort of the ENV515 (travoprost XR) Phase II trial to treat patients with glaucoma. (Source: Drug Development Technology)
Source: Drug Development Technology - February 6, 2017 Category: Pharmaceuticals Source Type: news
Glaukos touts IOP reduction in pseudophakic iStent study
Glaukos (NYSE:GKOS) today released data from a study of its iStent trabecular micro-bypass stent, touting reduced intraocular pressure when implanted in pseudophakic eyes with open-angle glaucoma.
Data from the study was recently published in the Journal of Glaucoma, the Laguna Hills, Calif.-based company said.
Glaukos’ iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP, the company said. Pseudophakic eyes are eyes in which the natural lens has been removed and replace...
Source: Mass Device - December 12, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news
Izba (Travoprost Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 6, 2016 Category: Drugs & Pharmacology Source Type: news
Travatan (Travoprost) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 6, 2016 Category: Drugs & Pharmacology Source Type: news
Glaukos touts 3-year iStent data
Glaukos (NYSE:GKOS) today released 3-year results from a study of its iStent trabecular micro-bypass stents, touting a 43% reduction in mean intraocular pressure in glaucoma patients treated with the device.
Results were published in the journal Ophthalmology and Therapy this month, the Laguna Hills, Calif.-based company said.
Glaukos’ iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP, the company said.
Data in the prospective study came from 101 patients with prim...
Source: Mass Device - September 23, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news
Novartis taps Hospira-sale engineer exec Ball to revive slumping Alcon
Novartis (NYSE:NVS) is looking to revitalize its slumping Alcon eye care division by picking up medical vet Michael Ball, who recently organized Hospira’s $15 billion sale to Pfizer (NYSE:PFE).
Ball will replace previous Alcon chief Jeff George, the company announced today. Novartis CEO Joe Jimenez is reportedly putting Ball in control of reviving Alcon.
Alcon has been in a rut, with its glaucoma drug Travatan Z patent expiring last month, intraocular lens implant revenue slumping and an underperforming over-the-counter contact lens solution biz.
“If you look at the mistakes that were made that have led to the slow...
Source: Mass Device - January 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Alcon Inc. Hospira Inc. Novartis AG Pfizer Inc. Source Type: news
Glaukos touts 3-year iStent study data
Glaukos (NYSE:GKOS) said today data from a 3-year study of its iStent Trabecular micro-bypass stent indicated that it, along with cataract surgery, lowered mean intraocular pressure 36% and reduced mean glaucoma medications by 86% 3 years post-surgery.
The study reported a mean IP of 14.99 mmHg in 39 patients monitored after treatment for 3 years, compared to a mean preoperative IOP of 23.4 mmHG. The mean number of glaucoma medications used after 3 years dropped to 0.3, compared with a preoperative mean of 1.9 medications.
No operative complications were reported, but 5 secondary surgeries, 2 postoperative ocular ocular s...
Source: Mass Device - January 20, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Blog Glaukos Corp. Source Type: news
